A key APGI priority is to continue to build capacity in translational research by acquiring biological material and clinico-pathological data for all types of pancreatic disease, which will provide an unparalleled base for ongoing studies. The APGI incorporates the NSW Pancreatic Cancer Network (2006-2010) and the Australian Familial Pancreatic Cancer Cohort (AFPaCC) (2011-2014).
The APGI has multiple sub-studies investigating different aspects of pancreatic cancer diagnosis and treatment. We are always looking for more people to be involved in our research studies. Click to find out more about our current studies.
Individualised Molecular Pancreatic Cancer Therapy (IMPaCT) is a new Australian clinical trial looking at individualising the treatment of patients with metastatic pancreatic cancer.